Holen Sie sich die Stockscreener-App
3.40
2.41%
0.08
Handel nachbörslich:
3.40
Galecto Inc Aktie (GLTO) Neueste Nachrichten
12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC - Defense World
Galecto (NASDAQ:GLTO) Shares Down 3.4% – What’s Next? - Defense World
Galecto Reports First Quarter 2025 Operating and Financial Results - The Manila Times
Galecto Reports First Quarter 2025 Operating and Financial Resul - GuruFocus
Galecto Reports First Quarter 2025 Operating and Financial Results | GLTO Stock News - GuruFocus
Renaissance Technologies LLC Sells 6,338 Shares of Galecto, Inc. (NASDAQ:GLTO) - Defense World
Keppel DC REIT (OTCMKTS:KPDCF) Short Interest Up 133.4% in March - Defense World
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 133.6% in March - Defense World
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - benzinga.com
Galecto, Inc. Focuses on Oncology and Liver Diseases - TipRanks
Galecto stock hits 52-week low at $3.75 amid market challenges - Investing.com
Galecto stock hits 52-week low at $3.75 amid market challenges By Investing.com - Investing.com South Africa
Galecto stock hits 52-week low at $4.39 amid market challenges - MSN
Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON… - RTTNews
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Galecto (GLTO) Shares Rally Amid Positive Market Momentum - Stocks Telegraph
Galecto Reports Full-Year 2024 Financial Results - The Manila Times
Galecto Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galecto, Inc. Completes Strategic Review, Acquires Global Rights to GB3226 for Oncology and Liver Disease Focus - Nasdaq
Galecto Cuts Losses by $17M, Acquires Promising AML Drug Candidate - StockTitan
Galecto Inc expected to post a loss of $2.97 a shareEarnings Preview - TradingView
Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight - The Globe and Mail
Galecto stock plunges to 52-week low at $3.76 amid market challenges - Investing.com Australia
Galecto stock plunges to 52-week low at $3.76 amid market challenges By Investing.com - Investing.com South Africa
Galecto (GLTO) Projected to Post Quarterly Earnings on Friday - Defense World
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Galecto stock hits 52-week low at $4.20 amid market challenges - Investing.com Australia
Galecto stock hits 52-week low at $4.20 amid market challenges By Investing.com - Investing.com South Africa
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail
Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World
Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter
Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com
Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan
Where are the Opportunities in (GLTO) - Stock Traders Daily
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):